PCK2 and fatty liver disease: Ginsenoside Rb1 improves insulin resistance and hepatic steatosis through the activation of the STAT3 pathway, promoting glycolytic enzyme GLUT2 and suppressing gluconeogenic enzyme PEPCK [40,41].